关键信息
-
基因名
HLA-A*02:01&B2M&MAGE-A2(YLQLVFGIEV) Monomer
- 应用
-
别名
HLA-A*0201 & B2M & MAGE-A2 (YLQLVFGIEV)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&YLQLVFGIEV
-
分子量
38-44 kDa and 12 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
The study of recombinant proteins such as HLA-A*02:01, beta-2-microglobulin (B2M), and MAGE-A2 (specifically the peptide YLQLVFGIEV) is critical in understanding immune responses and the development of cancer immunotherapies. HLA-A*02:01 is a major histocompatibility complex (MHC) Class I molecule that plays a vital role in presenting tumor-associated antigens to CD8+ T cells. MAGE-A2, a cancer-testis antigen, is expressed in various tumors but not in normal tissues, making it an appealing target for immunotherapy. The specific peptide YLQLVFGIEV derived from MAGE-A2 is recognized by T cells in individuals carrying the HLA-A*02:01 allele. By generating a monomeric recombinant protein that includes HLA-A*02:01 and B2M in complex with the MAGE-A2 peptide, researchers aim to elucidate the molecular interactions between the MHC molecule and the T cell receptor. This could contribute to a deeper understanding of T cell activation and specificity, ultimately aiding the development of targeted cancer immunotherapies that enhance the body's ability to recognize and eliminate tumor cells. Such studies not only advance the field of cancer immunology but also pave the way for personalized medicine approaches, where therapies can be tailored based on an individual's unique antigenic profile.
